An interim analysis of a phase 1/2 trial of quizartinib combined with azacitidine or low dose cytarabine in 52 AML patients (irrespective of FLT3 mutations) demonstrated an ORR of 67% [48]. Here, FLT3 is linked to acute myeloid leukemia.